...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Microencapsulation: Microcapsules Liposomes Nanoparticles Microcells Microspheres >Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery
【24h】

Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery

机译：含环丙沙星的脂质体的配制和体外评估

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In order to develop a niosome-encapsulated ciprofloxacin (CPFX) HCI formulation for pulmonary delivery, the feasibility of encapsulation of CPFX in niosomes, its stability and nebulization capability was evaluated. Various combinations of nonionic surfactants with cholesterol were used to prepare the formulations. The in vitro deposition data of the niosomal formulations were examined using an Andersen cascade impactor. Formulations composed of Span 60 and Tween 60 in combination with 40 mol% of cholesterol exhibited high encapsulation efficacy and stability and also had fine particle fraction and nebulization efficiency of about 61.9% ± 1.0 and 77.9 ± 2.8, respectively. Minimal inhibitory concentration of the niosomal CPFX against some pulmonary pathogens were lower than free CPFX. Using the MTT assay in human lung carcinoma cell line (A549), niosome-entrapped CPFX showed significantly lower cytotoxicity in comparison to the free drug. These results indicate that niosome can be used as a carrier for pulmonary delivery of CPFX via nebulization.
机译：为了开发用于肺部递送的脂质体包裹的环丙沙星（CPFX）HCl制剂，评估了CPFX包裹在脂质体中的可行性，稳定性和雾化能力。非离子表面活性剂与胆固醇的各种组合用于制备制剂。使用安德森（Andersen）级联撞击器检查了该脂质体制剂的体外沉积数据。由Span 60和Tween 60结合40摩尔％的胆固醇组成的制剂表现出高的包封效果和稳定性，并且细颗粒分数和雾化效率分别约为61.9％±1.0和77.9±2.8。血浆CPFX对某些肺病原体的最低抑制浓度低于游离CPFX。在人肺癌细胞系（A549）中使用MTT分析，与游离药物相比，包裹着脂质体的CPFX显示出明显更低的细胞毒性。这些结果表明，脂质体可以用作通过雾化肺部递送CPFX的载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号